Effect of magnesium and omega 3 co-supplementation supplement in Sarcopenic Elderly
- Conditions
- Condition 1: Sarcopenia. Condition 2: Intrinsic capacity.Muscle wasting and atrophy, not elsewhere classifiedM62.5
- Registration Number
- IRCT20090822002365N30
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 66
Complete and sign informed consent
Age 60-84 years
Diagnosis of possible sarcopenia according to update of Asian Working Group for Sarcopenia (AWGS) (hand grip strength less than 28 kg in men and less than 18 kg in women)
Impaired intrinsic capacity according to the first step of ICOPE guidelines of the World Health Organization
Required no or some support with self-care (feeding, bathing, dressing, toileting).
Taking any supplements containing magnesium and omega-3 during the last 2 months
Taking any supplements containing more than 100 mg magnesium
Acute cardiovascular diseases, acute infection, and acute cerebrovascular disease
Severe cardiac, liver, kidney dysfunction, autoimmune
Uncontrolled diabetes
Dementia, Parkinsons disease, and mental illnesses
unable to provide informed consent because of aphasia, deafness, and blindness
Physically-handicapped, disability, and use of a wheelchair or walker
Taking hormonal drugs
smoking
Acute illness (cold, corona and any other viral-bacterial-fungal disease)
Taking steroidal and non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics, laxatives and laxatives
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method